Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence
Stephan Ehrhardt1,*, Chan Xie2,*, Nan Guo1, Kenrad Nelson1,3,4, and Chloe L. Thio3,5
+
Author Affiliations
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America
2Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China
3Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States of America
4Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America
5Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America
For correspondence: Chloe L. Thio, MD, Professor of Medicine, Johns Hopkins University, 855 N Wolfe St, Suite 520, Baltimore, MD 21205, Ph: 410-614-6088, Email: [email protected]
↵* These authors contributed equally to this work.
Abstract
Lamivudine and tenofovir disoproxil fumarate (TDF) are both active against hepatitis B virus (HBV). Due to its potency, high genetic barrier to resistance, and safety during pregnancy, TDF may be useful to prevent HBV transmission from mother-to-child, which is the leading cause of transmission globally. Despite the safety record of lamivudine and TDF in pregnancy, the labels for both of these drugs recommend against their use during breastfeeding. In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.
同时服用拉米夫定或富马酸替诺福韦酯母乳喂养:证据的审查
斯蒂芬Ehrhardt1,*,陈Xie2,*,南果1,Kenrad Nelson1,3,4,和Chloe L. Thio3,5
"In a hepatitis B virus real-life cohort, tenofovir treatment during pregnancy was well-tolerated, including in patients treated from the first trimester. No safety issues were reported for breastfeeding while on tenofovir up to 1 year," Stern told MedPage Today, at the American Association for the Study of Liver Diseases meeting.
In this review, we discuss the data regarding lamivudine and TDF use during pregnancy and breastfeeding and find that the exposure to the drug is lower from breastfeeding than from in utero exposure. Thus, the data do not support the contraindication to their use during breastfeeding.
这句总结句,表示哺乳里的乳汁的暴露要少于子宫里的,这些数据不能支持禁止哺乳。作者: wangxinghao 时间: 2015-8-7 10:14
Limited published experience with tenofovir during breastfeeding in HIV-positive mothers and HIV-negative mothers treated for hepatitis B infection indicates that the exposure of the infant to the drug is trivial. A few infants have been breastfed during maternal tenofovir therapy and no adverse effects have been seen. An expert review of available data concluded that there is currently no justification for contraindicating the use of tenofovir for hepatitis B during breastfeeding.[1]
In the United States and other developed countries, HIV-infected mothers should generally not breastfeed their infants. In countries in which no acceptable, feasible, sustainable and safe replacement feeding is available, World Health Organization guidelines recommend that all women with an HIV infection who are pregnant or breastfeeding should be maintained on antiretroviral therapy for at least the duration of risk for mother-to-child transmission. Mothers should exclusively breastfeed their infants for the first 6 months of life; breastfeeding with complementary feeding should continue through 12 months of life. The first choice regimen for nursing mothers is tenofovir, efavirenz and either lamivudine or emtricitabine. If these drugs are unavailable, alternative regimens include: 1) zidovudine, lamivudine and efavirenz; 2) zidovudine, lamivudine and nevirapine; or 3) tenofovir, nevirapine and either lamivudine or emtricitabine. Exclusively breastfed infants should also receive 6 weeks of prophylaxis with nevirapine.[2][3] 作者: wangxinghao 时间: 2015-8-7 14:13